
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING,Nov. 19,2024-- With the support of the RiDYMO® platform,we are able to comprehensively explore various potential targets in drug development,including protein-protein interactions,kinases,